Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 4, 2014, Pages 459-468

  Kline, J A ^a   Nordenholz, K E ^b   Courtney, D M ^c   Kabrhel, C ^d   Jones, A E ^e   Rondina, M T ^f   Diercks, D B ^g   Klinger, J R ^h   Hernandez, J ⁱ  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ Department of Emergency Medicine Carolinas ^*  (United States)

Author keywords

Pulmonary embolism; Quality of life; Randomized controlled trial; Thrombolytic therapy; Ventricular function, right

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ARTICLE; BRAIN HEMORRHAGE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE INTOLERANCE; FATAL INTRACRANIAL HEMORRHAGE; FEMALE; FUNCTIONAL STATUS; HOSPITAL; HUMAN; HYPOTENSION; INTRASPINAL HEMORRHAGE; LUNG EMBOLISM; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGHT VENTRICLE DYSFUNCTION; SHOCK; SHORT FORM 36; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD DISEASE; ADULT; AGED; BLEEDING; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MORTALITY; PROBABILITY; PROSPECTIVE STUDY; PULMONARY EMBOLISM; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; QUALITY OF LIFE; SHOCK; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84898040877     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12521     Document Type: Article

References (35)

1. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 1: 1788-830.
2. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-315.
3. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-84S.
4. Worster A, Smith C, Silver S, Brown MD, Worster A, Smith C, Silver S, Brown MD. Evidence-based emergency medicine/critically appraised topic. Thrombolytic therapy for submassive pulmonary embolism? [Review] [18 refs]. Ann Emerg Med 2007; 50: 78-84.
5. Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2009: CD004437.
6. Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O'Neil BJ, Thompson JR, Hiestand B, Briese BA, Pendleton RC, Miller CD, Kline JA. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57: 700-6.
7. Stein PD, Matta F, Alrifai A, Rahman A. Trends in case fatality rate in pulmonary embolism according to stability and treatment. Thromb Res 2012; 130: 841-6.
8. PEITHO Investigators. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 2012; 163: 33-8.
9. Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, Nordenholz KE, Diercks DB, Rondina MT, Klinger JR. Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emerg Med Australas 2013; 25: 515-26.
10. Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Kaptein AA, Huisman MV. Quality of life in long-term survivors of acute pulmonary embolism. Chest 2010; 138: 1432-40.
11. Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. Respir Med 2010; 104: 1744-9.
12. Klok FA, Tijmensen JE, Haeck ML, van Kralingen KW, Huisman MV. Persistent dyspnea complaints at long-term follow-up after an episode of acute pulmonary embolism: results of a questionnaire. Eur J Intern Med 2008; 19: 625-9.
13. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status six months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009; 136: 1202-10.
14. Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, Cangemi D, Terrazzino G, Parrinello G, Sarullo FM, Baglini R, Paterna S, Di PP. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci 2011; 341: 33-9.
15. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol 2013; 111: 273-7.
16. Otero R, Oribe M, Ballaz A, Jimenez D, Uresandi F, Nauffal D, Conget F, Rodriguez C, Elias T, Jara L, Cayuela A, Blanco I, Barbera J. Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thromb Res 2011; 127: 303-8.
17. Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: a systematic review. Thromb Res 2008; 122: 763-73.
18. Vazquez SR, Freeman A, van Woerkom RC, Rondina MT. Contemporary issues in the prevention and management of postthrombotic syndrome. Ann Pharmacother 2009; 43: 1824-35.
19. Kline JA, Hernandez J, Rose G, Norton HJ, Camargo CA Jr. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med 2006; 34: 2773-80.
20. Crapo RO, Enright PL, Zeballos RJ. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
21. Kubo SH, Schulman S, Starling RC, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York Heart Association classification. J Card Fail 2004; 10: 228-35.
22. Hays RD, Sherbourne CD, Mazel RM. The Rand 36-item health survey 1.0. Health Econ 1993; 2: 217-27.
23. Kahn SR, Lamping DL, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I; VETO Study Investigators. VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. J Clin Epidemiol 2006; 59: 1049-56.
24. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996; 86: 726-8.
25. Lan GKK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
26. Stevinson BG, Hernandez-Nino J, Rose G, Kline JA. Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients. Eur Heart J 2007; 28: 2517-24.
27. Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, Balsemin F, Campanini M, Ghirarduzzi A, Casazza F. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125: e82-6.
28. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010; CD001100.
29. van Es J, den Exter PL, Kaptein AA, Andela CD, Erkens PM, Klok FA, Douma RA, Mos IC, Cohn M, Kamphuisen PW, Huisman MV, Middeldorp S. Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thromb Res 2013; 132: 500-5.
30. Nieto JA, Solano R, Trapero IN, Ruiz-Gimenez N, Fernandez-Capitan C, Valero B, Tiberio G, Bura-Riviere A, Monreal M. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb Res 2013; 132: 175-9.
31. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294: 2203-9.
32. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vascular Medicine 2000; 5: 91-5.
33. Lewis GD, Bossone E, Naeije R, Grunig E, Saggar R, Lancellotti P, Ghio S, Varga J, Rajagopalan S, Oudiz R, Rubenfire M. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation 2013; 128: 1470-9.
34. Puhan MA, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Schunemann HJ. Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 2007; 101: 308-16.
35. Penaloza A, Kline J, Verschuren F, Courtney DM, Zech F, Derrien B, Vielle B, Armand-Perroux A, Thys F, Roy PM. European and American suspected and confirmed pulmonary embolism populations: comparison and analysis. J Thromb Haemost 2012; 10: 375-81.